Leah Finberg
Phoenix, AZNPI 1275685067
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,330, more than ten times the $72 reported in 2019.
Across 298 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$911
- AstraZeneca$769
- Sanofi$677
- Boehringer Ingelheim$441
- Regeneron Healthcare Solutions, Inc.$421
- Insmed, Inc.$415
- plus $3K from 29 others
What the payments were for
- Consulting fees$351%
- Food & beverage$6,36497%
- Education$1362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 59 | $911 |
| AstraZeneca | 33 | $769 |
| Sanofi | 26 | $677 |
| Boehringer Ingelheim | 17 | $441 |
| Regeneron Healthcare Solutions, Inc. | 19 | $421 |
| Insmed, Inc. | 10 | $415 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $351 |
| CSL Behring | 11 | $320 |
| Grifols USA, LLC | 10 | $246 |
| Mylan Specialty L.p. | 9 | $211 |
| Verona Pharma, Inc. | 7 | $205 |
| United Therapeutics Corporation | 9 | $189 |
| Pfizer | 8 | $164 |
| Genentech USA, Inc. | 9 | $150 |
| Sanofi-aventis U.S. LLC | 2 | $136 |
| Viatris Specialty LLC | 5 | $120 |
| Actelion Pharmaceuticals US, Inc. | 4 | $107 |
| Baxter Healthcare | 6 | $96 |
| Amgen | 4 | $75 |
| Electromed, Inc. | 7 | $72 |
| Biocryst US Sales Co., LLC | 3 | $62 |
| Advanced Respiratory, Inc | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| ADMA Biomanufacturing LLC | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Lilly USA, LLC | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $28 |
| Kaleo, Inc. | 1 | $27 |
| Harmony Biosciences LLC | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 35 | $212,022 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $65,110 |
| Dupixent SyringeDupilumab | 13 | $49,837 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $23,531 |
| Arnuity ElliptaFluticasone Furoate | 63 | $21,259 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $18,007 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $17,878 |
| Spiriva HandihalerTiotropium Bromide | 12 | $12,153 |
| Spiriva RespimatTiotropium Bromide | 12 | $11,435 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $11,124 |
| DuleraMometasone/Formoterol | 20 | $10,072 |
| Qvar RedihalerBeclomethasone Dipropionate | 29 | $8,516 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $5,511 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $3,623 |
| Ipratropium Bromide | 62 | $3,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $320 | $212,02235 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $911 | $127,907206 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $441 | $29,31336 claims |
| AstraZenecaSymbicort | $769 | $11,12426 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $41 | $8,51629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.